A pioneering T-cell therapy is demonstrating the potential to combat some of the deadliest brain tumors in children, offering a new avenue for treatment against the leading cause of cancer-related deaths in pediatric patients. This innovative approach trains a child's own immune system to identify and attack cancerous cells, a method that has previously shown success against blood cancers but has faced challenges with solid tumors.
Targeting Solid Tumors
The trial, conducted at Children's National Hospital in Washington, D.C., marks the first human test of this specific T-cell therapy for pediatric brain tumors. Researchers reported that the therapy enabled children's immune systems to effectively recognize and eliminate brain tumor cells. Notably, some participants have remained disease-free for years following treatment. The therapy targets three specific proteins commonly found in pediatric brain tumors: WT1, PRAME, and Survivin. This multi-target approach aims to kill more cancer cells and reduce the likelihood of recurrence.
Challenges in Pediatric Brain Cancer Treatment
Brain tumors present significant challenges due to the blood-brain barrier, a natural defense mechanism that can also prevent treatments like chemotherapy from reaching the tumor. In some cases, drugs must be administered directly into the brain or surrounding fluid. Furthermore, brain tumors are often composed of diverse cell types, meaning a treatment might eliminate some cells while allowing others to survive and regrow the cancer.
The children involved in this trial were diagnosed with aggressive forms of cancer, including diffuse intrinsic pontine glioma (DIPG) and relapsed central nervous system (CNS) tumors. These pediatric cancers are particularly difficult to treat, with limited options and existing therapies often carrying severe side effects.
How T-cell Therapy Works
T-cell therapy, sometimes referred to as "living medicine," harnesses the body's natural ability to fight disease. The process begins with extracting T-cells, a type of white blood cell, from a patient's blood. These cells are then sent to a specialized facility where they are genetically engineered to recognize and attack cancer. This reprogramming is achieved by introducing a deactivated virus that carries new genetic instructions, transforming the T-cells into CAR T-cells.
Once engineered, the CAR T-cells are multiplied to a therapeutic dose, often in the millions or billions. They are then infused back into the patient via an IV, a procedure that typically takes less than an hour. Unlike chemotherapy, which can harm healthy cells, T-cell therapy is designed to be more targeted and less aggressive, potentially paving the way for long-term remission.
Next Steps for the Therapy
Researchers have successfully established a manufacturing process for the T-cell therapy, identified a maximum tolerated dose, and defined an initial safety profile. The next phase for this treatment is a move into a Phase 2 trial, which is a critical step toward seeking FDA approval and making the therapy accessible to children in need.